Clinical guidelines for HCV RNA testing continue to evolve with the approval of new DAAs

A sensitive, real-time PCR-based assay is recommended for HCV RNA testing.1
To monitor treatment efficacy, HCV RNA should be measured at specific time points:

From the 2014 AASLD Recommendations on Treatment of Hepatitis C1

Stay current with clinical guidelines and recommendations for HCV testing
by visiting the links below:

For additional HCV resources from The American Journal of Medicine, visit the link below:

*For HARVONI, end of treatment may be week 8, 12, or 24.
For VIEKIRA PAK, end of treatment may be week 12 or 24.
Discontinuation of HCV treatment is recommended if viral load has increased >10-fold on repeat testing at week 6.

References:

1.
American Association for the Study of Liver Diseases (AASLD). Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org. Updated October 8, 2014. Accessed November 24, 2014.
2.
HARVONI [full prescribing information]. Foster City, CA: Gilead Sciences, Inc.; 2014.
3.
VIEKIRA PAK [full prescribing information]. North Chicago, IL. AbbVie, Inc.; 2014.
4.
OLYSIO® [full prescribing information]. Titusville, NJ: Janssen Therapeutics, Division of Janssen Products, LP; 2014.
5.
SOVALDI [full prescribing information]. Foster City, CA: Gilead Sciences, Inc.; 2013.